|1.||Smith, Paul D: 13 articles (12/2015 - 08/2007)|
|2.||Huynh, Hung: 6 articles (08/2012 - 01/2007)|
|3.||Xing, Mingzhao: 5 articles (11/2015 - 12/2007)|
|4.||Wong, Kwok-Kin: 4 articles (11/2014 - 12/2008)|
|5.||Dent, Paul: 4 articles (04/2012 - 03/2008)|
|6.||Grant, Steven: 4 articles (04/2012 - 03/2008)|
|7.||Eckhardt, S Gail: 4 articles (02/2012 - 05/2008)|
|8.||Balmanno, Kathryn: 4 articles (02/2012 - 11/2009)|
|9.||Cook, Simon J: 4 articles (02/2012 - 11/2009)|
|10.||Roth, Jack A: 4 articles (05/2011 - 11/2009)|
02/01/2015 - "Western blot analysis and immunohistochemical staining revealed that treatment with AZD6244 or BEZ235 could significantly reduce the phosphorylation level of ERK1/2 or AKT in HCT116 tumor tissues. "
01/01/2014 - "Western blot analysis and immunohistochemical staining revealed that AZD6244 alone reduced ERK1/2 phosphorylation, angiogenesis, and tumor cell proliferation. "
01/01/2014 - "AZD6244 could inhibit the tumor growth of NCI-H1993, but slightly inhibit the tumor growth of NCI-1975 and NCI-H460. "
01/01/2014 - "Mice were randomly assigned to treatment with AZD6244, BEZ235, AZD6244 plus BEZ235, or control for 3 weeks, then all mice were sacrificed and tumor tissues were subjected to western blot analyses and immunohistochemical staining. "
01/01/2013 - "Plasma and tumor drug levels and the time course for recovery of ERK signaling and S-phase were measured in tumor-bearing mice treated for 48 hours with AZD6244 and then monitored for 48 hours off treatment. "
|2.||Stomach Neoplasms (Stomach Cancer)
01/01/2015 - "For absence of NRAS, KRAS and BRAF mutation, SGC7901 and BGC823 gastric cancer cells were relative resistance to AZD6244 in vitro. "
11/01/2014 - "KRAS amplification was associated with worse clinical outcomes, and the KRAS gene mutation predicted sensitivity to the MEK1/2 inhibitor AZD6244 in gastric cancer cell lines. "
01/01/2015 - "Targeting inhibition of p-ERK by AZD6244 suppress gastric cancer xenografts by blockage of angiogenesis without systemic toxicity. "
01/01/2015 - "However, the anti-tumor and anti-angiogenesis efficacy of AZD6244 on gastric cancer has not been well characterized. "
09/01/2009 - "AZD6244 (ARRY-142886) enhances the therapeutic efficacy of sorafenib in mouse models of gastric cancer."
|3.||Colorectal Neoplasms (Colorectal Cancer)
11/15/2009 - "We conclude that AZD6244 is effective in colorectal cancer cell lines with BRAF or KRAS mutations. "
02/01/2012 - "We have used colorectal cancer cell lines harbouring mutations in B-Raf or K-Ras to model acquired resistance to the MEK1/2 inhibitor selumetinib (AZD6244). "
12/01/2010 - "Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer."
01/01/2010 - "To identify potential mechanisms of acquired drug resistance, we generated clones resistant to the allosteric MEK inhibitor AZD6244 from two BRAF V600E mutant colorectal cancer cell lines that are highly sensitive to MEK or BRAF inhibition. "
11/15/2009 - "We analysed cell proliferation in a panel of 19 colorectal cancer cell lines and found no simple correlation between BRAF or KRAS mutation and sensitivity to AZD6244, though cells that harbour neither mutation tended to be resistant. "
|4.||Breast Neoplasms (Breast Cancer)
01/01/2012 - "These indicate us that MTDH is a candidate marker to predict the clinical efficacy of AZD6244 and targeting MTDH could overcome the resistance to AZD6244 in breast cancer cells."
09/01/2014 - "Here, we report that AZD6244 repressed cell growth and induced apoptosis and G1-phase arrest in the breast cancer cell lines MDA-MB-231 and HCC1937. "
01/01/2012 - "In conclusion knockdown MTDH can enhance the breast cancer cells sensitivity to AZD6244 via regulating the expression and activity of FOXO3a. "
01/01/2012 - "When the MTDH was downregulated, the breast cancer cells exhibited a significantly increased sensitivity to AZD6244 as measured by MTT assay. "
01/01/2012 - "Here we report that the resistance to AZD6244 can be reserved by downregulating MTDH in breast cancer cell lines. "
|5.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
12/01/2013 - "Here, we identified a novel MEK1/2 inhibitor, CZ0775, and compared its cytotoxic effects to those of AZD6244 (selumetinib) in non-small cell lung cancer (NSCLC) cell lines harboring EGFR mutations. "
01/01/2010 - "Our previous work showed the importance of activated AKT in mediating resistance of non-small cell lung cancer (NSCLC) to AZD6244. "
08/01/2008 - "We examined the activity of AZD6244 in a panel of non-small cell lung cancer and a panel of cell lines representing many cancer types using in vitro growth assays. "
10/01/2010 - "This study aimed to evaluate the efficacy and safety of AZD6244 versus pemetrexed as second- or third-line treatment in patients with advanced non-small cell lung cancer (NSCLC). "
10/01/2010 - "A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens."
|3.||Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)
|5.||Factor IX (PTC)
|7.||sorafenib (BAY 43-9006)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Drug Therapy (Chemotherapy)